Cargando…
Diazoxide for Lowering Insulin Levels in Breast Cancer Patients
Diazoxide is a nondiuretic benzothiadiazine that produces hyperglycemia by lowering insulin levels through activation of ATP‐sensitive K1‐channels and stimulating insulin degradation in the lysosomal system. Its effect on cancer growth is discussed.
Autores principales: | Fink, Michael K., Klement, Rainer J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388385/ https://www.ncbi.nlm.nih.gov/pubmed/28400489 http://dx.doi.org/10.1634/theoncologist.2016-0402 |
Ejemplares similares
-
Diazoxide Causality Assessment of a Pericardial Effusion in a Child with Kabuki Syndrome
por: Maffre, Irene, et al.
Publicado: (2019) -
Face masks in radiation oncology clinics: based on evidence or source of mistakes?
por: Klement, Rainer J., et al.
Publicado: (2020) -
The risk‐benefit ratio of Covid‐19 vaccines: Publication policy by retraction does nothing to improve it
por: Walach, Harald, et al.
Publicado: (2022) -
The danger of diazoxide in the neonatal intensive care unit
por: Desai, Jay, et al.
Publicado: (2021) -
Prevalence and safety of diazoxide in the neonatal intensive care unit
por: Gray, Keyaria D, et al.
Publicado: (2018)